These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 38961036)

  • 1. Multiple myeloma: signaling pathways and targeted therapy.
    Lu Q; Yang D; Li H; Niu T; Tong A
    Mol Biomed; 2024 Jul; 5(1):25. PubMed ID: 38961036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
    Hu J; Hu WX
    Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targeted therapies and combinations for the treatment of multiple myeloma.
    Agarwal A; Mahadevan D
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
    Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic strategies for multiple myeloma.
    Mimura N; Hideshima T; Anderson KC
    Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targeted agents in the treatment of multiple myeloma.
    Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
    Lin CH; Tariq MJ; Ullah F; Sannareddy A; Khalid F; Abbas H; Bader A; Samaras C; Valent J; Khouri J; Anwer F; Raza S; Dima D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategies for targeting cell adhesion in multiple myeloma.
    Nair RR; Gebhard AW; Emmons MF; Hazlehurst LA
    Adv Pharmacol; 2012; 65():143-89. PubMed ID: 22959026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
    Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
    J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
    Anwer F; Gee KM; Iftikhar A; Baig M; Russ AD; Saeed S; Zar MA; Razzaq F; Carew J; Nawrocki S; Al-Kateb H; Cavalcante Parr NN; McBride A; Valent J; Samaras C
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):397-405. PubMed ID: 31036508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
    Anreddy N; Hazlehurst LA
    J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
    Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
    Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.
    Akhtar S; Ali TA; Faiyaz A; Khan OS; Raza SS; Kulinski M; Omri HE; Bhat AA; Uddin S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
    Ramakrishnan V; Kumar S
    Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
    Vrábel D; Pour L; Ševčíková S
    Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.